Background: A study to analyse tumor markers (CEA, CA125, CA15.3, CA19.9, CYFRA 21-1, and NSE) for metastasis detection in lung cancer patients.
Methods: Serum tumor markers from 73 lung cancer patients were measured before they were diagnosed. After lung cancer diagnosis, tumor markers were analyzed for the detection of distant metastases.
Results: In NSCLC patients CYFRA 21-1 and NSE showed differences between stage IV and any of the other stages, p <0.05. The accuracy for metastasis detection was AUC = 81.5 % for CYFRA 21-1 and AUC = 78.6 % for NSE. CYFRA 21-1 (OR = 1.406; 95 % CI, 1.087 - 1.821, p <0.01) and NSE (OR = 1.197; 95 % CI, 1.011 - 1.416, p <0.05) were independent predictors for metastasis presence. No tumor marker showed significant differences ac-cording to stages in SCLC patients.
Conclusions: CYFRA 21-1 could be used as a screening tool for metastasis detection in lung cancer patients without symptoms of metastasis as well as CYFRA 21-1 and NSE in NSCLC patients.
DOI: Clin. Lab. 2011;57:1011-1014